Prospects of Using PCSK9 Inhibitors for Acute Coronary Syndrome
https://doi.org/10.35401/2541-9897-2024-9-2-124-128
Abstract
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme involved in the regulation of blood cholesterol levels by binding to low-density lipoprotein receptors and promoting their degradation. Pivotal studies have shown that PCSK9 inhibition by monoclonal antibodies, alirocumab and evolocumab, and the small interfering RNA (inclisiran) reduces the risk of cardiovascular diseases in individuals with coronary heart disease. However, the place of the PCSK9 inhibitors in treatment of patients with acute coronary syndrome has not been determined yet. The article discusses studies on the addition of PCSK9 inhibitors to therapy during the acute phase of myocardial infarction as well as pathophysiological prerequisites for their use.
Supporting agencies: The study was supported by the Kuban Science Foundation under scientific project No. МФИ-20.1/63.
About the Authors
A. M. Namitokov
Scientific Research Institute – Ochapovsky Regional Clinical Hospital No. 1; Kuban State Medical University
Russian Federation
Russian Federation
Alim M. Namitokov, Cand. Sci. (Med.), Head of Cardiology Unit No. 2 for Patients with Myocardial Infarction, Scientific Research Institute – Ochapovsky Regional Clinical Hospital No. 1; Associate Professor at Therapy Department No. 1, Faculty of Continuing Professional Development and Retraining, Kuban State Medical University
ulitsa 1 Maya 167, Krasnodar, 350086
V. K. Zafiraki
Kuban State Medical University
Russian Federation
Russian Federation
Vitaliy K. Zafiraki, Dr. Sci. (Med.), Professor at Therapy Department No. 1, Faculty of Continuing Professional Development and Retraining
Krasnodar
K. V. Karabakhtsieva
Kuban State Medical University
Russian Federation
Russian Federation
Karina V. Karabakhtsieva, Resident, Therapy Department No. 1, Faculty of Continuing Professional Development and Retraining
Krasnodar
References
1. Roth GA, Mensah GA, Johnson CO, et al; GBD-NHLBIJACC Global Burden of Cardiovascular Diseases Writing Group. Global burden of cardiovascular diseases and risk factors, 1990- 2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982–3021. Published correction appears in J Am Coll Cardiol. 2021;77(15):1958–1959. PMID: 33309175. PMCID: PMC7755038. https://doi.org/10.1016/j.jacc.2020.11.010
2. Chow CK, Islam S, Bautista L, et al. Parental history and myocardial infarction risk across the world: the INTERHEART study. J Am Coll Cardiol. 2011;57(5):619–627. PMID: 21272754. https://doi.org/10.1016/j.jacc.2010.07.054
3. Seidah NG, Benjannet S, Wickham L, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A. 2003;100(3):928–933. PMID: 12552133. PMCID: PMC298703. https://doi.org/10.1073/pnas.0335507100
4. Almontashiri NA, Vilmundarson RO, Ghasemzadeh N, et al. Plasma PCSK9 levels are elevated with acute myocardial infarction in two independent retrospective angiographic studies. PLoS One. 2014;9(9):e106294. PMID: 25180781. PMCID: PMC4152257. https://doi.org/10.1371/journal.pone.0106294
5. Burchardt P, Rzeźniczak J, Dudziak J, et al Evaluation of plasma PCSK9 concentrations, transcript of LDL receptor, as well as the total number of monocyte LDL receptors in acute coronary syndrome patients. Cardiol J. 2016;23(6):604–609. PMID: 27665855. https://doi.org/10.5603/CJ.a2016.0068
6. Fyfe T, Baxter RH, Cochran KM, Booth EM. Plasma-lipid changes after myocardial infarction. Lancet. 1971;2(7732):997–1001. PMID: 4108108. https://doi.org/10.1016/s0140-6736(71)90322-9
7. Navarese EP, Kolodziejczak M, Winter MP, et al. Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: the PCSK9- REACT study. Int J Cardiol. 2017;227:644–649. PMID: 27810295. https://doi.org/10.1016/j.ijcard.2016.10.084
8. Schwartz GG, Steg PG, Szarek M, et al; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(2):2097–2107. PMID: 30403574. https://doi.org/10.1056/NEJMoa1801174
9. Sabatine MS, Giugliano RP, Keech AC, et al; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–1722. PMID: 28304224. https://doi.org/10.1056/NEJMoa1615664
10. Khan SA, NazA, Qamar Masood M, Shah R. Meta-analysis of inclisiran for the treatment of hypercholesterolemia. Am J Cardiol. 2020;134:69–73. PMID: 32892993. https://doi.org/10.1016/j. amjcard.2020.08.018
11. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/ PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol. 2019;73(24):e285–e350. Published correction appears in J Am Coll Cardiol. 2019;73(24):3237–3241. PMID: 30423393. https://doi.org/10.1016/j.jacc.2018.11.003
12. Mach F, Baigent C, Catapano AL, et al; ESC Scientific Document Group. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–188. Published correction appears in Eur Heart J. 2020;41(44):4255. PMID: 31504418. https://doi.org/10.1093/eurheartj/ehz455
13. Li S, PengY, Wang X, et al Cardiovascular events and death after myocardial infarction or ischemic stroke in an older Medicare population. Clin Cardiol. 2019;42(3):391–399. PMID: 30697776. PMCID: PMC6712383. https://doi.org/10.1002/clc.23160
14. Abtan J, Bhatt DL, Elbez Y, et al; REACH Registry Investigators. Residual ischemic risk and its determinants in patients with previous myocardial infarction and without prior stroke or TIA: insights from the REACH Registry. Clin Cardiol. 2016;39(11):670–677. PMID: 27588731. PMCID: PMC6490735. https://doi.org/10.1002/clc.22583
15. Murphy A, Hamilton G, Andrianopoulos N, et al; Melbourne Interventional Group. One-year outcomes of patients with established coronary artery disease presenting with acute coronary syndromes. Am J Cardiol. 2019;123(9):1387–1392. PMID: 30797559. https://doi.org/10.1016/j.amjcard.2019.01.037
16. Chen H, Chen X. PCSK9 inhibitors for acute coronary syndrome: the era of early implementation. Front Cardiovasc Med. 2023;10:1138787. PMID: 37200976. PMCID: PMC10185746. https://doi.org/10.3389/fcvm.2023.1138787
17. Koskinas KC, Windecker S, Pedrazzini G, et al. Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients with Acute Coronary Syndromes (EVOPACS). J Am Coll Cardiol. 2019;74(20):2452–2462. PMID: 31479722. https://doi.org/10.1016/j.jacc.2019.08.010
18. Mehta SR, Pare G, Lonn EM, et al. Effects of routine early treatment with PCSK9 inhibitors in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a randomised, double-blind, sham-controlled trial. EuroIntervention. 2022;18(11):e888–e896. PMID: 36349701. PMCID: PMC9743253. https://doi.org/10.4244/EIJ-D-22-00735
19. Trankle CR, Wohlford G, Buckley LF, et al. Alirocumab in acute myocardial infarction: results from the Virginia Commonwealth University Alirocumab Response Trial (VCU-AlirocRT). J Cardiovasc Pharmacol. 2019;74(3):266–269. PMID: 31356537. PMCID: PMC8336145. https://doi.org/10.1097/FJC.0000000000000706
20. Räber L, Ueki Y, Otsuka T, et al; PACMAN-AMI collaborators. Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial. JAMA. 2022;327(18):1771–1781. PMID: 35368058. PMCID: PMC8978048. https://doi.org/10.1001/jama.2022.5218
21. Zanchin C, Koskinas KC, Ueki Y, et al. Effects of the PCSK9 antibody alirocumab on coronary atherosclerosis in patients with acute myocardial infarction: a serial, multivessel, intravascular ultrasound, near-infrared spectroscopy and optical coherence tomography imaging study-rationale and design of the PACMAN-AMI trial. Am Heart J. 2021;238:33–44. PMID: 33951415. https://doi.org/10.1016/j.ahj.2021.04.006
22. Nicholls SJ, Kataoka Y, Nissen SE, et al. Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction. JACC Cardiovasc Imaging. 2022;15(7):1308–1321. PMID: 35431172. https://doi.org/10.1016/j.jcmg.2022.03.002
23. Zhang Y, Suo Y, Yang L, et al. Effect of PCSK9 inhibitor on blood lipid levels in patients with high and very-high CVD risk: a systematic review and meta-analysis. Cardiol Res Pract. 2022;2022:8729003. PMID: 35529059. PMCID: PMC9072011. https://doi.org/10.1155/2022/8729003
Review
For citations:
Namitokov A.M., Zafiraki V.K., Karabakhtsieva K.V. Prospects of Using PCSK9 Inhibitors for Acute Coronary Syndrome. Innovative Medicine of Kuban. 2024;(2):124-128. (In Russ.) https://doi.org/10.35401/2541-9897-2024-9-2-124-128
Views:
349
Email this article 
